Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Scher

Showing results (431-440 of 692) with videos related to

Pageof 70
Sort By:
Cancer Chemotherapy and Pharmacology|October 25, 2011
Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trialEmmanuel S Antonarakis, Michael A Carducci, Mario A Eisenberger, et al.
Journal of Circulating Biomarkers|March 15, 2021
Development of an immunofluorescent AR-V7 circulating tumor cell assay - A blood-based test for men with metastatic prostate cancerDavid Lu, Rachel Krupa, Melissa Harvey, et al.
Journal of the National Cancer Institute|September 10, 1998
Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinomaC Cordon-Cardo, A Koff, M Drobnjak, et al.
Cancer Chemotherapy and Pharmacology|July 4, 2013
A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancerDana E Rathkopf, Joel Picus, Arif Hussain, et al.
The Journal of Urology|March 1, 1988
M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urotheliumC N Sternberg, A Yagoda, H I Scher, et al.
Radiology|January 31, 2014
Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survivalHebert Alberto Vargas, Cecilia Wassberg, Josef J Fox, et al.
JAMA Oncology|December 13, 2019
Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical TrialsAndrew J Armstrong, Mohammed Al-Adhami, Ping Lin, et al.
Investigational New Drugs|September 4, 2025
A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genesKaren A Autio, Christos E Kyriakopoulos, Paul Palyca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapyMichael J Morris, Timothy Akhurst, Steven M Larson, et al.
Cancer Research|October 4, 2000
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivoL M Butler, D B Agus, H I Scher, et al.
Pageof 70

Showing results (431-440 of 692) with videos related to

Sort By:
Pageof 70
Cancer Chemotherapy and Pharmacology|October 25, 2011
Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trialEmmanuel S Antonarakis, Michael A Carducci, Mario A Eisenberger, et al.
Journal of Circulating Biomarkers|March 15, 2021
Development of an immunofluorescent AR-V7 circulating tumor cell assay - A blood-based test for men with metastatic prostate cancerDavid Lu, Rachel Krupa, Melissa Harvey, et al.
Journal of the National Cancer Institute|September 10, 1998
Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinomaC Cordon-Cardo, A Koff, M Drobnjak, et al.
Cancer Chemotherapy and Pharmacology|July 4, 2013
A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancerDana E Rathkopf, Joel Picus, Arif Hussain, et al.
The Journal of Urology|March 1, 1988
M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urotheliumC N Sternberg, A Yagoda, H I Scher, et al.
Radiology|January 31, 2014
Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survivalHebert Alberto Vargas, Cecilia Wassberg, Josef J Fox, et al.
JAMA Oncology|December 13, 2019
Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical TrialsAndrew J Armstrong, Mohammed Al-Adhami, Ping Lin, et al.
Investigational New Drugs|September 4, 2025
A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genesKaren A Autio, Christos E Kyriakopoulos, Paul Palyca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapyMichael J Morris, Timothy Akhurst, Steven M Larson, et al.
Cancer Research|October 4, 2000
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivoL M Butler, D B Agus, H I Scher, et al.
Pageof 70